—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Halozyme Therapeutics Inc (HALO) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for HALO, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.53 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How HALO has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.53 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Halozyme Therapeutics Inc moved 0.53% on average · correlation 0.13 · higher than 55% of US names
  • Beta, last 3 months 0.67 about the same as over the year
  • On the 10 worst bond days −0.95% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +2.47% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against HALO on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Halozyme Therapeutics Inc

HALO in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Halozyme develops and licenses an enzyme called rHuPH20, which lets injectable biologic drugs be given under the skin instead of by intravenous infusion. It sells this enzyme technology to large drug makers, who build it into subcutaneous versions of their antibody treatments, and it also sells a small number of its own products directly. Revenue comes mainly from royalties and milestone payments tied to partner drugs such as those licensed to Roche, Pfizer and other pharmaceutical companies. It is based in San Diego.
Where it sits in the stack
Halozyme sits in our Healthcare sleeve, in the biotechnology sector, outside the AI build-out universe our index tracks. It behaves as a licensing business: partner pharmaceutical companies are the customers of its enzyme platform, and its own revenue is a function of how many of their subcutaneous drugs reach and stay on the market.
Who it is priced against
The diary does not carry a peer group for Halozyme; it can be read alongside other drug-delivery and formulation licensors that pharmaceutical companies use to convert intravenous drugs into subcutaneous ones.
Why Closelooknet tracks it
Halozyme holds no seat in our index and the diary has not quoted it. It carries a Closelooknet score, but with only one module scored so far, so the score is still being built.
What the diary watches
Whether existing licensing and royalty agreements with its pharmaceutical partners are renewed or extended, since its revenue depends on those partner drugs remaining in use.

Halozyme Therapeutics Inc (HALO) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Halozyme Therapeutics Inc (HALO)?

Halozyme Therapeutics Inc trades as HALO on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is HALO in a Closelooknet index?

Not currently — Halozyme Therapeutics Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does HALO trade against its moving averages?

Uptrend stack intact: Trades +5.5% vs the 50-day and +39.3% vs the 200-day average, 6.1% below the 52-week high and +79.2% off the 52-week low; a golden cross printed 66 sessions ago. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Halozyme Therapeutics Inc compare with its peers?

Against its peer group (Biotechnology · US), Halozyme Therapeutics Inc (HALO) sits 6.1% below its 52-week high, 5.5% above its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to HALO in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Halozyme Therapeutics Inc trade when bond yields rise?

Over the past year Halozyme Therapeutics Inc had a beta of 0.53 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 55% of US names. On the 10 sessions in which long bonds fell most it moved −0.95% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Halozyme Therapeutics Inc do?

Halozyme develops and licenses an enzyme called rHuPH20, which lets injectable biologic drugs be given under the skin instead of by intravenous infusion. It sells this enzyme technology to large drug makers, who build it into subcutaneous versions of their antibody treatments, and it also sells a small number of its own products directly. Revenue comes mainly from royalties and milestone payments tied to partner drugs such as those licensed to Roche, Pfizer and other pharmaceutical companies. The diary does not carry a peer group for Halozyme; it can be read alongside other drug-delivery and formulation licensors that pharmaceutical companies use to convert intravenous drugs into subcutaneous ones.

Where does Halozyme Therapeutics Inc sit in the AI build-out?

Halozyme sits in our Healthcare sleeve, in the biotechnology sector, outside the AI build-out universe our index tracks. It behaves as a licensing business: partner pharmaceutical companies are the customers of its enzyme platform, and its own revenue is a function of how many of their subcutaneous drugs reach and stay on the market. Halozyme holds no seat in our index and the diary has not quoted it. It carries a Closelooknet score, but with only one module scored so far, so the score is still being built.

What does this page show?

A live price chart with SMA overlays and drawing tools for HALO, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.